macro

60 Degrees Pharmaceuticals receives Nasdaq delisting notice

Nasdaq has told 60 Degrees Pharmaceuticals it faces delisting after its shares traded below $1 for 30 straight business days. The company has requested a hearing.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

According to TradingView, citing filings with the SEC, Nasdaq informed the company on November 19, 2026 that its share price had stayed under $1.00 for 30 consecutive business days. That breaches Nasdaq Listing Rule 5550(a)(2), and the exchange has decided to delist the securities.

The company does not qualify for a standard compliance period because it carried out reverse stock splits within the previous year. It asked for a hearing by November 27, 2026. Until the Panel rules, the suspension and the Form 25-NSE filing are on hold.

why it matters

For markets, this is a sign of financial pressure at a small drug developer. The news concerns a single stock and is unlikely to move the broader market, but the Panel's decision will determine whether the shares stay listed on Nasdaq.

tags

instruments

60 Degrees Pharmaceuticals

sources

  1. 60 Degrees Pharmaceuticals Received Notice of Delisting — TradingView, 20 November 2026 at 22:03 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗